4506.T Sumitomo Dainippon Pharma Co., Ltd.
¥1,583 -1.68%
Asia · Pharmaceuticals
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.68%
YTD
-16.10%
P/E
—
P/B
—
ROE
—
Div yield
—
Beta
0.39
Market cap
—
RSI (14)
52
Next earnings
—
Previous session
close of Oct 8, 2026 · EOD, no live order bookOpen
¥1,650
Close
¥1,583
VWAP (n/a)
—
Day high
¥1,670
Day low
¥1,583
Volume
3.2M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Sumitomo Pharma (TSE:4506) Stock Looks Below Fair Value On Earnings Power
Yahoo Finance · Sep 4
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa
Yahoo Finance · Aug 12
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia
Yahoo Finance · Jul 30
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia
Yahoo Finance · Jun 15
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
Yahoo Finance · Jun 10
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
Yahoo Finance · Jun 1
Headlines via Yahoo Finance · links open the source · not an endorsement.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell 4506.T. Try it in the Lab to size a position and see the risk.